CD74 modulates B cell, T cell and dendritic cell responses [14,15] and milatuzumab, an anti-CD74 antibody, has orphan drug status for the treatment of multiple myeloma and chronic lymphocytic leukemia [20]. The gene discussed is CD74; the disease is AL amyloidosis.